Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer

This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients
with metastatic or locally advanced platinum-resistant ovarian cancer.

Patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be
administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on
a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. Approximately 70
patients may be evaluated in this study with approximately 35 patients in each treatment
arm.